Enrollment halted in Avastin breast cancer trial

updated 7:48 p.m. ET Sept. 25, 2009

NEW YORK - Swiss drug developer Roche said Friday six cases of patients with heart failure symptoms prompted a halt to enrollment in a National Cancer Institute sponsored study of its blockbuster drug Avastin.

The U.S. National Cancer Institute and U.S. Eastern Cooperative Oncology Group, which is conducting the study, told Roche it suspended adding new patients to the late-stage study because of the heart failure symptoms in the early-stage breast cancer patients. Symptoms include shortness of breath and fatigue, along with swelling in certain parts of the body.

The study focuses on Avastin's effectiveness as an adjuvant in combination with chemotherapy. The drug is already approved to treat various stages of colon, lung, brain, and kidney cancer and is one of Roche's biggest moneymakers.

The study is designed to test for cardiovascular safety and focused on the first 200 patients enrolled, from which the six patients showed heart failure symptoms. The study was designed for a halt in enrollment if six of the first 200 patients showed signs of heart failure.

Five patients have recovered; one uncertain
Five patients have since returned to normal levels and Roche said it is waiting for information on the sixth patient. Roche said the rate of heart failure is consistent Avastin's profile.

Moving ahead, the study's safety board is evaluating the data and will determine the next steps. There are 3,439 patents enrolled in the study and will have to give their consent to continue dosing after being given the updated information.

The study goal was to enroll 4,950 patients.

In April, Avastin failed a similar late-stage study focused on early-stage cancer and the company said it would continue study the drug's effectiveness in combination with chemotherapy for other types of cancer.

Roche had been partners with South San Francisco, California-based Genentech on Avastin prior to paying $46.8 billion for the biotechnology company. Avastin, which is approved as a treatment for various stages of colon, lung, brain, and kidney cancer, was Genentech's biggest seller. It is now one of Roche's most lucrative drugs, reaching U.S sales $2.69 billion in 2008. Wall Street has projected the drug could exceed $10 billion in sales by 2015.

Also in msnbc.com Health Be thankful. You're not like mom and dad Coherent after coma? Not so sure Stifling anger at work can be harmful Docs to patients: Pay up or lose care Two-tiered medicine: Clinics with 2 doors   Animal Tracks: Eye candy for animal lovers

MORE FROM HEALTH

Health Section Front

Curry compound kills cancer cells, study shows   Busting breast myths   Look and feel your best after cancer Husband and wife both victims of breast cancer I’m 27 and about to have a double mastectomy Clue hints at how breast cancer spreads KISS drummer Criss: Men get breast cancer too Suzanne Somers works to ‘Knockout’ cancer After breast cancer: ‘They can rebuild me’ Pose nude? No way. After breast cancer? OK! Health Section Front   Add Health headlines to your news reader: